US Drug Recall Register
Class III · Low risk Ongoing Initiated Nov 26, 2025 (9 months ago)

Cisatracurium Besylate Injection USP

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Subpotent product:out of specification assay results observed during long term stability testing.

What was recalled

Cisatracurium Besylate Injection USP, 10 mg/5 mL* (2mg/mL), 10 x 5 mL Single-dose Vials per Carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, Single-dose 5 mL vial NDC 70069-141-01; 10x5 mL single dose vial per Carton NDC 70069-141-10.

Recalling firm
Somerset Therapeutics LLC
NDC code
70069-141-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0236-2026

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Cisatracurium recalls

See all
Class III · Low risk Ongoing

Cisatracurium Besylate Injection USP

Reason Subpotent product:out of specification assay results observed during long term stability testing.

Somerset Therapeutics LLC NDC 70069-161-01 D-0238-2026
Class III · Low risk Ongoing

Cisatracurium Besylate Injection USP

Reason Subpotent product:out of specification assay results observed during long term stability testing.

Somerset Therapeutics LLC NDC 70069-151-01 D-0237-2026
Class I · High risk Terminated

Cisatracurium Besylate Injection

Reason Labeling: Label mix-up: Carton of Cisatracurium Besylate Injection, USP was observed to contain ten vials mislabeled as Phenylephrine Hydrochloride Injection, USP, but confirmed to contain Cisatracurium

Meitheal Pharmaceuticals Inc NDC 71288-712-05 D-0286-2021
Class II · Moderate risk Terminated

Cisatracurium Besylate Injection

Reason Incorrect/ Undeclared Excipient: Firm is recalling product due to an incorrect statement of Preservative free on the individual carton label. The vial label and outer carton label contain the correct statement of 0.9% benzyl alcohol added as a preservative.

Fresenius Kabi USA, LLC NDC 63323-417-10 D-0819-2016
Class II · Moderate risk Terminated

Cisatracurium Besylate active pharmaceutical ingredient packaged…

Reason Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Attix Pharmaceuticals D-589-2015